Drug Profile
Research programme: trasferrin conjugates - Panther Biotechnology
Alternative Names: Research programme: trasferrin conjugates - Faulk PharmaceuticalsLatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Faulk Pharmaceuticals
- Developer Panther Biotechnology
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Parasitic infections; Viral infections
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Parasitic infections in USA (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Viral infections in USA (unspecified route)